Cyclerion Therapeutics

Cyclerion Therapeutics

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1b/Clin2a
  • Therapy area: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
  • Drug types: CVV, NEU, GEN, RAR, PSY
  • Lead product: CY6463
  • Product link:
  • Funding: $18M stock Jun 2021; $24M stock Jul 2020

job board

Short description:

Small Molecules

Drug notes:

Also Clin1b/Clin2a Alzheimer's with vascular pathology, Clin1b/Clin2a cognitive impairment in schizophrenia, Clin1 undisclosed; CY3018 Clin0 undisclosed

Long description:

Cyclerion is leveraging knowledge of cyclic-GMP (cGMP) to address serious CNS diseases. Using their systems biology approach, Cyclerion has identified CNS diseases in which the NO-sGC-cGMP pathway plays a central role including both neurodegenerative and neuropsychiatric diseases. These diseases are associated with deficits in the NO-sGC-cGMP. By developing sGC stimulators, such as CY6463, Cyclerion is hoping to restore disrupted signaling while maintaining endogenous NO regulation. CY6463 is Cyclerion’s first CNS-penetrant sGC stimulator that has shown benefits in multiple animal models by improving neuronal function, reducing neuro-inflammation and enhancing cellular bioenergetics. CY6463 is now in clinical trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy